GPC3 and neoplasm: Under the guidance of the surface-modified aptamer, the G-NK cells could bind to GPC3+ tumor cells and subsequently trigger cell apoptosis and necrosis in vitro, leading to enhanced immunotherapeutic efficiency in vivo after enrichment at the tumor site.